General Information

Age Group

Adults

Status

Recruiting

Protocol Number

INOVA 2026-13

Background Information

The objective(s) of this study is to:

  • To evaluate the safety and tolerability of PF-08046033 in participants with advanced solid tumors
  • To identify the maximum tolerated dose (MTD) or maximum administered dose (MAD) of PF-08046033
  • To identify a recommended dose and schedule of PF-08046033 for expansion (RDE)

For more information, please visit https://clinicaltrials.gov/study/NCT07519655

Offered At

8081 Innovation Park Drive
Fairfax, VA 22031
Principal Investigator

Amin Benyounes, MD

Eligibility Information

  • Participants must have histologically-confirmed metastatic or unresectable locally advanced NSCLC, ESCC, or cutaneous melanoma.
  • Participants must have disease that has progressed on or be unable to tolerate standard treatments (Part 1) or 1-2 prior systemic therapies (Part 2).
  • Participants must have measurable disease.
  • Eastern Cooperative Oncology Group (ECOG) performance status is 0-1

Ineligibility Information

  • Participants with known clinically active central nervous system (CNS) metastases.
  • Participants with pre-existing neuropathy ≥Grade 2 per NCI CTCAE v 5.0.
  • Uncontrolled diabetes mellitus with hemoglobin (Hgb) A1C ≥10.0%.
  • Untreated clinically significant thromboembolic disease.
  • Previous exposure to GPNMB-targeted therapy.